bioAffinity Technologies, Inc. has filed a prospectus supplement with the SEC to offer up to $5.2 million in common stock. This filing is significant as it represents the company's ongoing efforts to raise capital for its operations and growth initiatives. The move indicates bioAffinity's strategy to leverage favorable market conditions and investor interest in the commercial physical and biological research sector.

Founded in San Antonio, Texas, bioAffinity Technologies operates under the SIC classification of Services-Commercial Physical & Biological Research. The company is publicly traded on the Nasdaq under the ticker symbols BIAF and BIAFW. Its recent filings include a prospectus supplement dated October 8, 2026, and an 8-K filed on October 29, 2026.

The latest filing, dated November 2, 2026, supplements and amends a prior prospectus, allowing the company to increase the aggregate amount of common stock it intends to sell. According to the filing, bioAffinity has already sold 114,672 shares for gross proceeds of approximately $1.3 million under the existing Sales Agreement with WallachBeth Capital LLC. The company now aims to offer an additional $3.4 million of its common stock.

As of the date of this prospectus supplement, the market value of bioAffinity's outstanding common stock held by non-affiliates is approximately $27.7 million. This valuation is based on 1,813,011 shares held by non-affiliates and a closing price of $15.27 per share as of September 4, 2026. The company plans to adhere to SEC regulations, ensuring that it does not exceed selling more than one-third of the aggregate market value of its common stock held by non-affiliates within a 12-month period.

Investors should note that investing in bioAffinity's common stock involves a high degree of risk, as highlighted in the prospectus. The company has emphasized the importance of reviewing the associated risk factors before making any investment decisions.

Looking ahead, bioAffinity Technologies may file additional updates or amendments as it continues to navigate its capital-raising efforts. The filing does not specify what actions will follow this prospectus supplement.